Trials / No Longer Available
No Longer AvailableNCT04371627
Viaskin® Peanut (DBV712) Expanded Access Protocol
Viaskin® Peanut (DBV712) Expanded Access Protocol in Peanut-Allergic Children
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- DBV Technologies · Industry
- Sex
- All
- Age
- 4 Years – 12 Years
- Healthy volunteers
- —
Summary
This is an open label expanded access program for male and female patients ≥ 4 years old.
Detailed description
This study is an open-label Intermediate-size EAP designed to provide treatment access for eligible Peanut-Allergic Children. This EAP entails visits every three months to assess patient status, safety, and to provide drug supply. Viaskin® Peanut treatment will continue until, in the clinical judgment of the Investigator, the patient is no longer benefiting from continuation of the treatment, the drug becomes approved and available by prescription, or the study is terminated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Viaskin Peanut | Daily epicutaneous delivery |
Timeline
- First posted
- 2020-05-01
- Last updated
- 2021-05-28
Source: ClinicalTrials.gov record NCT04371627. Inclusion in this directory is not an endorsement.